Our Products

Help shape patient care worldwide

UK laws and regulations limit the amount of product information that we can provide to the general public via our website. The product information on this website is intended for UK residents over the age of eighteen years only.


Adcirca® (tadalafil) ***





Abasaglar®(insulin glargine)*  

Humalog® (human insulin analogue)

Humulin® (human insulin)

Jentadueto® (metformin hydrochloride, linagliptin) **

Jardiance® (empagliflozin) **

Synjardy® (metformin hydrochloride, empagliflozin)**

Trajenta® (linagliptin) **

Trulicity® (dulaglutide)


Humatrope® (somatropin) 


Forsteo® (teriparatide)




Cymbalta® (duloxetine)

Strattera® (atomoxetine) 

Zyprexa® (olanzapine)

Zypadhera® (olanzapine pamoate monohydrate)

Prozac® (fluoxetine hydrochloride)


Alimta® (pemetrexed)  

Cyramza® (ramucirumab) 

Lartruvo® (olaratumab)





Cialis® (tadalafil)

Yentreve® (duloxetine)

Reporting Of Side Effects

Lilly advises patients who experience side effects to talk to their doctor or other health care professional. This includes any possible side effects not listed in the package leaflet. To report a side effect or product complaint with a Lilly product please call Lilly UK on 01256 315000.  Additionally, reporting forms and further information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of medicines.

The following Lilly medicines are subject to additional monitoring: Abasaglar®, Amyvid®, Cyramza®, Jardiance®, Lartruvo®, Olumiant®,  Portrazza®, Taltz®, Trulicity®, Synjardy® and Verzenios® . This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Lilly’s Medical Information team can be contacted on 01256 315 000.


* Lilly is the marketing authorisation holder (MAH) but either co promotes or co markets this product
** Lilly is not the marketing authorisation holder (MAH) but either promotes, markets or distributes this product
*** Lilly is the marketing authorisation holder (MAH) but does not promote this product